Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.
COVID-19-associated blood plasma inflammatory factors do not affect blood-brain barrier, study shows
It is now well documented that the coronavirus outbreak triggered a global health crisis. In this study, researchers wanted to know whether blood-brain barrier impairment
January 20, 2024